CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed
Drug / intervention
Methotrexatedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00006168
NCT00006168Phase 3Completed
CompareCT.gov

Ursodiol-Methotrexate for Primary Biliary Cirrhosis

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·interventional·Posted Aug 9, 2000·Updated Jan 13, 2010

In Brief

A Phase 3 clinical trial evaluating Methotrexate for Liver Cirrhosis, Biliary. Completed, across 12 sites.

Detailed Summary

The major thrust is to determine whether treatment of patients with Primary Biliary Cirrhosis (PBC) with Ursodiol (Ursodeoxycholic Acid-UDCA) plus methotrexate (MTX) is more effective than treatment with UDCA alone.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLiver Cirrhosis, Biliary
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
1994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 9, 2000
Enrollment StartJan 1, 1994
Study CompletionMar 1, 2004
TodayJul 2, 2026
Posted 25.9 years ago

Interventions

Methotrexatedrug